Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

About this update from Soleno Therapeutics, Inc.

[{"type":"image","alt":"Soleno Therapeutics","displaySize":"","headline":null,"caption":"Soleno Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":276,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/db2ea416cce39ac8cbe72553399abd48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JmW8yHWegMC9Qr4jr5A2lQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/db2ea416cce39ac8cbe72553399abd48","width":276,"height":110}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets.","length":400,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights","length":65,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"From approval on March 26, 2025 through December 31, 2025, Soleno reports:","length":74,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"1,250 patient start forms received, including 207 in the fourth quarter","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"630 unique prescribers, including 136 new prescribers in the fourth quarter","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"859 active patients on drug as of December 31, 2025","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Over 185 million lives covered","length":30,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":227,"olType":false}]},{"val":[{"type":"text","content":"Achieved profitability with positive net income of $20.9 million for the year.","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated $48.7 million of cash flow from operating activities in the fourth quarter.","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Invested $...

More updates from Soleno Therapeutics, Inc.